| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.10. | Coeptis Therapeutics Holdings, Inc. - S-4/A, Registration of securities, business combinations | 1 | SEC Filings | ||
| 01.10. | Coeptis Therapeutics: Coeptis Anchors $800M Valuation in Dual-Sector Strategy; Vanderbilt Report Publishes Coverage | 189 | ACCESS Newswire | BRISTOL, TN / ACCESS Newswire / October 1, 2025 / Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) today announced that The Vanderbilt Report has published coverage of the company following its recent... ► Artikel lesen | |
| 23.09. | Vanderbilt Report and Coeptis Therapeutics: Vanderbilt Report: Coeptis Shows How Biotech Can Fund Itself While Innovating | 2 | GlobeNewswire (USA) | ||
| 12.09. | Coeptis Therapeutics Holdings, Inc. - S-4/A, Registration of securities, business combinations | 1 | SEC Filings | ||
| 14.08. | Coeptis Therapeutics Holdings, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 09.08. | Coeptis Therapeutics Holdings, Inc. - S-4/A, Registration of securities, business combinations | - | SEC Filings | ||
| 22.07. | Coeptis Therapeutics: Coeptis (COEP) Extinguishes Convertible Note with YA II PN, Ltd | 1 | GlobeNewswire (USA) | ||
| COEPTIS THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 26.06. | Coeptis Therapeutics: Coeptis (COEP) Announces Filing of Registration Statement on Form S-4 with SEC in Connection with Proposed Transaction with Z Squared | 2 | GlobeNewswire (USA) | ||
| 26.06. | Coeptis Therapeutics Holdings, Inc. - S-4, Registration of securities, business combinations | - | SEC Filings | ||
| 03.06. | Coeptis Therapeutics Holdings, Inc. - 10-K/A, Annual Report | 1 | SEC Filings | ||
| 28.05. | Monarch Therapeutics and SNAP Biosciences, Inc., a Subsidiary of Coeptis Therapeutics Holdings Inc., Enter Licensing Agreement to Bolster SNAP-CAR NK Cell Therapy in Oncology | 1 | GlobeNewswire (USA) | ||
| 14.05. | Coeptis Therapeutics Holdings, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 25.04. | Coeptis Therapeutics, Inc. and Z Squared Inc. Announce Merger Agreement | 240 | GlobeNewswire (Europe) | WEXFORD, Pa., April 25, 2025 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (Nasdaq; COEP) ("Coeptis" or the "Company"), a biopharmaceutical and technology company focused on developing innovative... ► Artikel lesen | |
| 27.12.24 | Coeptis Therapeutics, Inc.: Coeptis Therapeutics Announces Reverse Stock Split | 305 | PR Newswire | WEXFORD, Pa., Dec. 27, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company focused... ► Artikel lesen | |
| 26.12.24 | Coeptis Therapeutics, Inc.: Coeptis Therapeutics Makes Bold Strides in Innovation with the Acquisition of NexGenAI Affiliates Network Platform and Launch of Coeptis Technologies | 451 | PR Newswire | Coeptis Aims to Bring AI Innovation in Biotechnology and Technology
WEXFORD, Pa., Dec. 26, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq:... ► Artikel lesen | |
| 03.12.24 | Coeptis Pharmaceuticals, Inc.: Coeptis Therapeutics Executes Binding Letter of Intent to Acquire Ai-powered Marketing Solutions for Biotech, Pharmaceutical and Other Industries | 167 | PR Newswire | The Acquisition of NexGenAI Affiliates Network Expands Company's Capabilities and Drives Innovation, Operational Efficiency, and Opportunity for Growth
WEXFORD... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AVIDITY BIOSCIENCES | 48,550 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026 | SAN DIEGO, Oct. 13, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics... ► Artikel lesen | |
| ARCELLX | 84,07 | 0,00 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 6,590 | 0,00 % | Ventyx Biosciences: NBC feiert Daten-Knall und +928% in 6 Monaten | Der Party-Herbst reißt nicht ab: Nach dem Tenbagger Minerva explodieren im No Brainer Club die nächsten Kurs-Granaten. Eine davon ist die Aktie von Ventyx Biosciences. Die Ventyx-Aktie hatte der No... ► Artikel lesen | |
| ADMA BIOLOGICS | 15,250 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 57,76 | 0,00 % | Mizuho startet Coverage für Kymera Therapeutics mit "Outperform" | ||
| HARMONY BIOSCIENCES | 29,600 | 0,00 % | Harmony Biosciences Rises 10.6% On Strong Q3 WAKIX Results And Upgraded Guidance | ||
| NUVALENT | 90,89 | 0,00 % | Nuvalent, Inc.: Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results | Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of... ► Artikel lesen | |
| TANGO THERAPEUTICS | 7,510 | 0,00 % | Tango Therapeutics Sub, Inc: Tango Therapeutics Announces $225 Million Financing | BOSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer... ► Artikel lesen | |
| NURIX THERAPEUTICS | 10,400 | 0,00 % | Nurix Therapeutics, Inc.: Nurix Initiates DAYBreak Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia | 600 mg once daily bexobrutideg oral dose cleared by global regulators for pivotal monotherapy trials in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Phase 2 DAYBreak trial initiated... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,720 | 0,00 % | Recursion Pharmaceuticals (RXRX) Surges 14% Ahead of Earnings | ||
| EVOTEC | 7,038 | +2,51 % | Übernahme von Vidac Pharma und Evotec? 400 Mrd. USD bei Pfizer, Merck und Co im Feuer! | Alarm bei Big Pharma! Donald Trump scheint bei der Reduzierung von Medikamentenpreisen ernst zu machen. Gleichzeitig laufen Patente bei Blockbustern aus und ein 400 Mrd. USD Umsatzausfall droht. Pfizer... ► Artikel lesen | |
| 89BIO | 14,800 | 0,00 % | Roche Launches Tender Offer To Acquire 89bio For $14.50/shr Plus CVR | SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY, RO.SW, ROG.SW) announced that it has launched a tender offer to acquire all outstanding common shares of 89bio, Inc. (ETNB). The offer includes... ► Artikel lesen | |
| COGENT BIOSCIENCES | 14,840 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces FDA Breakthrough Therapy Designation for Bezuclastinib | Detailed results from bezuclastinib's positive SUMMIT trial evaluating bezuclastinib in patients with NonAdvanced Systemic Mastocytosis planned for presentation at upcoming scientific conference this... ► Artikel lesen | |
| MAZE THERAPEUTICS | 29,900 | 0,00 % | Maze Therapeutics files to sell 9.23M shares of common stock for holders | ||
| PRAXIS PRECISION MEDICINES | 177,75 | 0,00 % | Praxis Precision Medicines prices $525M public offering |